Singapore, Singapore

Win Lwin Thuya

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: National University of Singapore, Sengenics Sdn Bhd. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Win Lwin Thuya. Retrieved from https://idiyas.com/inventor/win-lwin-thuya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Win Lwin Thuya: Innovator in Cancer Diagnostics

Introduction

Win Lwin Thuya is an inventor based in Singapore, SG. He has made significant contributions to the field of cancer diagnostics, particularly in the detection of biomarkers for Non-Small Cell Lung Cancer (NSCLC). Although he currently holds no granted patents, his work is noteworthy for its potential impact on medical diagnostics.

Latest Patent Applications

Win Lwin Thuya's latest patent application is titled "Detection of Biomarkers for Non-Small Cell Lung Cancer." This application describes a method for diagnosing NSCLC from a sample extracted from a subject by testing the sample for the presence of biomarkers. The biomarkers include autoantibodies against XAGE1D, LRRFIP2, and GAGE2C. The application also claims a method of manufacturing a kit and compositions comprising a panel of said antigens or exosomal autoantibodies.

Conclusion

Win Lwin Thuya's innovative approach to cancer diagnostics highlights the importance of research in the medical field. His work has the potential to improve diagnostic methods for Non-Small Cell Lung Cancer, contributing to better patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…